OutMatch Profile - Gilead

March 5, 2018

Gilead Stock

Gilead Sciences, Inc.
Company Type: Large Pharma
Region: United States, Worldwide
Cash Position: USD 25 510M
Therapeutic Focus: HIV/AIDS, Liver Diseases, Hematology/Oncology, Inflammation/Respiratory, Cardiovascular


Deal Activity

Gilead Data

Figure 1. Gilead Sciences, Inc. In-Licensing Deals and Acquisitions, 2013 through Present (March 2018)

Recent Deal Highlights:

COLLABORATION WITH SANGAMO THERAPEUTICS FOR ZINC FINGER NUCLEASE TECHNOLOGY PLATFORM

Total Size: USD 3 160M | Upfront: USD 150M | Therapeutic Area: Hematology/Oncology | Date: February 2018

PRESS

ACQUISITION OF CELL DESIGN LABS FOR SYNNOTCH AND THROTTLE TECHNOLOGY PLATFORMS

Total Size: USD 567M | Upfront: USD 175M | Therapeutic Area: Hematology/Oncology | Date: December 2017

PRESS

ACQUISITION OF KITE PHARMA FOR CHIMERIC ANTIGEN RECEPTOR AND ENGINEERED T CELL RECEPTOR THERAPIES

Total Size: USD 11 900M | Therapeutic Area: Hematology/Oncology | Date: August 2017

PRESS | SEC

R&D PIPELINE

Gilead Pipeline

Figure 2. Gilead Sciences, Inc. R&D Pipeline at present (March 2018)

Products from Recent Deals:

ACQUIRED KITE PHARMA CAR-T THERAPIES

Disease Area: Hematology/Oncology | Status: Diffuse Large B-Cell Lymphoma Phase III | Diffuse Large B-Cell Lymphoma Combination Phase II | Indolent Non-Hodgkin Lymphoma Phase II | Multiple Myeloma Phase I | Solid Tumors Phase I

ONO PHARMACEUTICAL PARTNERED BRUTON’S TYROSINE KINASE INHIBITOR

Disease Area: Hematology/Oncology | Status: Sjogren’s Syndrome Phase II | Chronic Lymphocytic Leukemia Phase II | B-Cell malignancies Phase I

ACQUIRED NIMBUS THERAPEUTIC ACETYL-COA CARBOXYLASE PROGRAM

Disease Area: Liver Diseases | Status: Non-alcoholic Steatohepatitis Phase II

BUSINESS DEVELOPMENT TEAM


Business profiles tailored to your asset.